Meloxicam

Meloxicam

SCHEMBL5273441

CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O.Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1

nearest known ligand 0.75

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PTGS2

The experimentally established mechanism targets of Meloxicam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 known ✓ P35354 4/20 0.75
PTGS1 P23219 6/20 0.75
KDM4E B2RXH2 3/20 0.73
CYP2C9 P11712 3/20 0.73
USP2 O75604 3/20 0.73
ABCB11 O95342 2/20 0.73
GLA P06280 1/20 0.73
EDNRA P25101 1/20 0.73
GAA P10253 1/20 0.73
CYP1A2 P05177 2/20 0.67
CYP3A4 P08684 2/20 0.67
CYP2D6 P10635 2/20 0.67
ALOX15 P16050 1/20 0.67
NFKB1 P19838 1/20 0.67
CYP2C19 P33261 1/20 0.67
BLM P54132 1/20 0.67
SLC22A6 Q4U2R8 1/20 0.67
SLC22A8 Q8TCC7 1/20 0.67
MAPK1 P28482 1/20 0.66
LMNA P02545 3/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Piroxicam SCHEMBL2722775 0.93 PTGS1 (0.85) PTGS1PTGS2KDM4ECYP2C9USP2
Piroxicam SCHEMBL6846290 0.91 PTGS1 (0.89) PTGS1PTGS2KDM4ECYP2C9USP2
Lornoxicam SCHEMBL1412269 0.88 ABCB11 (0.75) PTGS1PTGS2KDM4ECYP2C9USP2
Meloxicam SCHEMBL23589638 0.85 PTGS1 (1.00) PTGS1PTGS2KDM4ECYP2C9USP2
Tenoxicam SCHEMBL25343 0.85 PTGS1 (1.00) PTGS1PTGS2KDM4ECYP2C9USP2
Meloxicam SCHEMBL3752395 0.85 PTGS1 (1.00) PTGS1PTGS2KDM4ECYP2C9USP2
Meloxicam SCHEMBL3576 0.85 PTGS1 (1.00) PTGS1PTGS2KDM4ECYP2C9USP2
Piroxicam SCHEMBL9114300 0.85 PTGS1 (0.74) PTGS1PTGS2KDM4ECYP2C9USP2
Piroxicam SCHEMBL1444687 0.85 ABCB11 (0.79) PTGS1PTGS2KDM4ECYP2C9USP2
Meloxicam SCHEMBL332632 0.84 PTGS1 (0.98) PTGS1PTGS2KDM4ECYP2C9USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11185590-B2 Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2021-11-30 US claimed
US-10071162-B2 Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2018-09-11 US claimed
US-20070202208-A1 Anti-Inflammatory Pharmaceutical Compositions For Reducing Inflammation And The Treatment Or Prevention Of Gastric Toxicity META PROTEOMICS, LLC 2007-08-30 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070202208-A1 Anti-Inflammatory Pharmaceutical Compositions For Reducing Inflammation And The Treatment Or Prevention Of Gastric Toxicity VIP, ALPI, HPGDS PTGS2 41/4885PTGS1 12/4885KDM4E 4629/4885
US-11185590-B2 Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition SI, PIM1, PIM3 PTGS2 4664/4885PTGS1 4442/4885KDM4E 1216/4885
US-10071162-B2 Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition PIM1, PPARD, KCNN1 PTGS2 4607/4885PTGS1 4253/4885KDM4E 892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.